Crescent Biopharma, Inc. has 15 Schedule 13D or 13G filings on record since 2025-07-08. 8 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Fairmount Funds Management LLC | 16.52% | 6,593,385 | SCHEDULE 13D/A, 2026-07-20 | 2026-07-16 |
| Fmr LLC | 15% | 4,133,514 | SCHEDULE 13G/A, 2026-02-05 | 2025-12-31 |
| 1Globe Capital LLC | 10.3% | 1,425,432 | SCHEDULE 13G/A, 2025-10-14 | 2025-10-07 |
| Bvf Partners L P | 9.99% | 1,387,863 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| Venrock Healthcare Capital Partners III, L.P. | 9.5% | 2,666,064 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| ForGrowth III PA B.V. | 6.1% | 1,677,852 | SCHEDULE 13G, 2025-12-11 | 2025-12-08 |
| Balyasny Asset Management L.P. | 6.03% | 1,662,917 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Vestal Point Capital, LP | 5.4% | 1,500,000 | SCHEDULE 13G, 2026-02-17 | 2025-12-31 |
| Tang Capital Management, LLC | 4.21% | 1,160,000 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Logos Global Management LP | 4.1% | 575,000 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
Purpose of Transaction (Item 4)
Fairmount Funds Management LLC
Item 4 of the Statement is hereby amended and supplemented as follows: Fund II purchased the Ordinary Shares and Pre-funded Warrants referenced in Item 3 for investment purposes. Lock-Up Agreement In connection with the Company's underwritten public offering of Ordinary Shares and Pre-Funded Warrants that closed on July 16, 2026, the Reporting Persons entered into a customary lock-up letter agreement (the "Lock-Up Agreement") with Jefferies LLC and TD Securities (USA) LLC acting as the Representatives (collectively, the "Representatives") of the underwiters party to to an underwriting agreement with the Company. Pursuant to the Lock-Up Agreement, the Reporting Persons agreed to refrain from selling shares of the Company's securities without the consent of the Representatives, and other customary lock-up conditions, for a period of 60 days following the date of the final prospectus supplement for the offering. The foregoing description of the Lock-Up Agreement does not purport to be complete and is qualified in its entirety by reference to the Form of Lock-Up Agreement, which is filed as Exhibit 99.2 to this Schedule 13D and incorporated herein by reference. Pre-Funded Warrants The Pre-Funded Warrants purchased by Fund II in the offering have an exercise price of $0.001, are immediately exercisable at any time after the date of issuance and will not expire. A holder of Pre-Funded Warrants may not exercise the warrant if the holder, together with its affiliates, would …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-07-20; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-08 | Fmr LLC | 10.2% | SCHEDULE 13G |
| 2025-08-14 | Bvf Partners L P | 9.99% | SCHEDULE 13G/A |
| 2025-08-14 | Logos Global Management LP | 4.1% | SCHEDULE 13G/A |
| 2025-08-20 | 1Globe Capital LLC | 6.45% | SCHEDULE 13G |
| 2025-10-09 | Tang Capital Management, LLC | 5.04% | SCHEDULE 13G |
| 2025-10-14 | 1Globe Capital LLC | 10.3% | SCHEDULE 13G/A |
| 2025-12-08 | Fairmount Funds Management LLC | 18.53% | SCHEDULE 13D/A |
| 2025-12-11 | ForGrowth III PA B.V. | 6.1% | SCHEDULE 13G |
| 2026-02-05 | Fmr LLC | 15% | SCHEDULE 13G/A |
| 2026-02-17 | Vestal Point Capital, LP | 5.4% | SCHEDULE 13G |
| 2026-02-17 | Venrock Healthcare Capital Partners III, L.P. | 9.5% | SCHEDULE 13G/A |
| 2026-05-15 | Balyasny Asset Management L.P. | 5.48% | SCHEDULE 13G |
| 2026-05-15 | Tang Capital Management, LLC | 4.21% | SCHEDULE 13G/A |
| 2026-07-20 | Fairmount Funds Management LLC | 16.52% | SCHEDULE 13D/A |
| 2026-08-14 | Balyasny Asset Management L.P. | 6.03% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for Crescent Biopharma, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.